Advancing precision medicine with molecular glues
Magnet Biomedicine’s modular TrueGlue™ technology enables the systematic discovery of molecular glues toward the treatment of human disease.
The Science
TrueGlues are small molecules that localize drug effects to disease-relevant targets in complex with tissue-enriched “presenter” proteins.
Magnet is advancing precision medicine through the rational selection of protein pairs and systematic design of monovalent molecular glues. Combining the benefits of small molecule drugs with the advantages conferred by cooperative interactions with a presenter protein, TrueGlues offer the potential to address the most challenging targets in a tissue-localized manner.
Since their discovery more than three decades ago, molecular glues have demonstrated vast potential to treat human disease.
Recent advancements in the field have largely focused on targeted protein degradation, leaving the expansive potential of molecular glues untapped. Magnet is reimagining what’s possible with molecular glues by venturing beyond known protein-protein interactions (PPIs) and analyzing the broad protein landscape to pair target proteins with endogenous presenter proteins for maximum therapeutic impact.
Uniquely enabled by its platform capabilities, Magnet is pioneering the discovery of novel molecular glue medicines to address a range of indications with high unmet need, including cancer, immune disorders, and cardiovascular disease.
Rationally designed TrueGlues localize drug effects to disease-relevant tissues, providing unique opportunities to maximize the therapeutic index by minimizing on-target-off-tissue toxicity.
TrueGlues offer opportunities to induce biological synergy, target historically undruggable proteins, and alter protein localization to enable mechanisms of action that are not attainable by traditional small molecule inhibitors.
OUR TECHNOLOGY
Building upon recent advances in proteomics, screening, and bioinformatics, we believe the time is now to execute on this long-standing goal of rational molecular glue discovery.
Our TrueGlue discovery platform combines state-of-the-art screening technologies utilizing diverse chemical libraries and human biology–driven target and presenter selection. Our process integrates diverse streams of in-house and external data to discover and exploit novel molecular glue mechanisms of action. Magnet’s TrueGlue technology can be applied in an indication-agnostic manner to discover molecular glues with a wide range of target modulation, drug-like properties, and selectivity.
OUR PEOPLE
Magnet’s team combines decades of drug‑discovery experience and an innovative TrueGlue pipeline.
Our diverse scientific expertise has enabled a multipronged approach that pushes the boundaries of existing technology to advance TrueGlues as a new therapeutic modality with the potential to alter the treatment landscape in cancer, autoimmune, and cardiovascular diseases.
- All
- Leadership
- Team
- Founders
- Board Of Directors
- Scientific Advisory Board
Brian Safina, PhD
President & Chief Executive Officer
Bret Williams, PhD
Senior Vice President of Research
Matthew Hayward, PhD
Vice President of Drug Discovery
Jennifer Franklin
Vice President of Operations
Kristina Burow
Managing Director at ARCH Venture Partners
Thomas Cahill, MD, PhD
Founder and Managing Partner at Newpath Partners
Ramnik Xavier, MD, PhD
Scientific Advisory Board Chair
Benjamin F. Cravatt, PhD
Founder & Advisor
David A. Spiegel, MD, PhD
Founder & Advisor
Michael Rosbash, PhD
Founder & Advisor
Richa Saxena, PhD
Founder & Advisor
Stuart Schreiber, PhD
Founder & Advisor
Joshua Alper, PhD
Biomolecular Discovery
Chelsea Ankeny
Office Manager
Austin Carr, PhD
Proteomics
Xiao Chen, PhD
Biology
YiQun Chen
Biology
Diala Ezzeddine, PhD
Business Development
Jessica Gasser, PhD
Biology
Shubhroz Gill, PhD
Biology
Adarsh Godbole
Protein Production
Yuan Hu, PhD
Computational Chemistry
Bruce Hua, PhD
Chemistry
Liam Hudson, PhD
Chemistry
Anita Kim
Lab Operations
Chueh-Ling Kuo, PhD
Biomolecular Discovery
Jason Lowe, PhD
Chemistry
Alyssa Lutservitz, MS
Informatics
Ashish Maurya, PhD
Biology
Jessica McManus
Biology
Francesca Pisanzio
Biology
James Ralff
Compound Management
David Rhee, PhD
Proteomics
Andrew Reidenbach, PhD
Biomolecular Discovery
Anthony Scruse, PhD
Chemistry
Luke Stamatakis, CPA
Finance & Accounting
Tom Tian, PhD
Biology
Tiffany Tsang, PhD
Biology
Go Watanabe, PhD
Protein Production
Teruki Watanabe, PhD
Chemistry
Lauren Weiss
Biology
Hsin-Lan Wen, PhD
BiologyOur Investors
CAREERS
Magnet Biomedicine is building a world-class team to unleash the scientific breakthroughs and expertise of our founders.
We are looking for creative, thoughtful, science-first innovators to join our collaborative team. Come help us realize the potential of molecular glues to achieve the broadest possible impact for patients.
Sr. RA/Associate Scientist; Biophysics/Biochemistry
